BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 11205300)

  • 1. Effect of amifostine on neuroblastoma during high dose chemotherapy: in vivo and in vitro investigations.
    Renner S; Krümpelmann S; Bruchelt G; Wiesinger H; Niethammer D; Klingebiel T
    Anticancer Res; 2000; 20(6B):4531-8. PubMed ID: 11205300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pilot study of addition of amifostine to melphalan, carboplatin, etoposide, and cyclophosphamide with autologous hematopoietic stem cell transplantation in pediatric solid tumors-A pediatric blood and marrow transplant consortium study.
    Ozkaynak MF; Sahdev I; Gross TG; Levine JE; Cheerva AC; Richards MK; Rozans MK; Shaw PJ; Kadota RP
    J Pediatr Hematol Oncol; 2008 Mar; 30(3):204-9. PubMed ID: 18376282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplantation.
    Hartmann JT; von Vangerow A; Fels LM; Knop S; Stolte H; Kanz L; Bokemeyer C
    Br J Cancer; 2001 Feb; 84(3):313-20. PubMed ID: 11161394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of amifostine as a chemoprotectant during high-dose chemotherapy in autologous peripheral blood stem cell transplantation.
    Cronin S; Uberti JP; Ayash LJ; Raith C; Ratanatharathorn V
    Bone Marrow Transplant; 2000 Dec; 26(11):1247-9. PubMed ID: 11149742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential of amifostine in high-dose chemotherapy and autologous hematopoietic stem cell transplantation.
    Phillips GL
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):53-6. PubMed ID: 12577245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melphalan combined with a carboplatin dose based on glomerular filtration rate followed by autologous stem cell rescue for children with solid tumours.
    Shaw PJ; Pinkerton CR; Yaniv I
    Bone Marrow Transplant; 1996 Dec; 18(6):1043-7. PubMed ID: 8971371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study for poor-prognosis lymphoma: augmentation of the "BEAM" regimen with escalating dose melphalan using amifostine cytoprotection and autologous hematopoietic stem cell transplantation--a preliminary report.
    Phillips GL; Abboud CN; Bernstein SH; Friedberg JW; Ifthikharuddin JJ; Lancet JE; Liesveld JL; Spreng E; Johnson V; Chapman M; Vesole DH
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):59-61. PubMed ID: 15726525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
    Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study.
    Matthay KK; Tan JC; Villablanca JG; Yanik GA; Veatch J; Franc B; Twomey E; Horn B; Reynolds CP; Groshen S; Seeger RC; Maris JM
    J Clin Oncol; 2006 Jan; 24(3):500-6. PubMed ID: 16421427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The incidence of hearing impairment after successful treatment of neuroblastoma.
    Simon T; Hero B; Dupuis W; Selle B; Berthold F
    Klin Padiatr; 2002; 214(4):149-52. PubMed ID: 12165893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose cyclophosphamide inhibition of humoral immune response to murine monoclonal antibody 3F8 in neuroblastoma patients: broad implications for immunotherapy.
    Kushner BH; Cheung IY; Kramer K; Modak S; Cheung NK
    Pediatr Blood Cancer; 2007 Apr; 48(4):430-4. PubMed ID: 16421906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amifostine and chemotherapy-related thrombocytopenia.
    Budd GT
    Semin Oncol; 1996 Aug; 23(4 Suppl 8):49-52. PubMed ID: 8783667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemoprotection in anticancer therapy: the emerging role of amifostine (WR-2721).
    Kurbacher CM; Mallmann PK
    Anticancer Res; 1998; 18(3C):2203-10. PubMed ID: 9703784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel intensive induction therapy for high-risk neuroblastoma utilizing sequential peripheral blood stem cell collection and infusion as hematopoietic support.
    Pradhan KR; Johnson CS; Vik TA; Sender LS; Kreissman SG
    Pediatr Blood Cancer; 2006 Jun; 46(7):793-802. PubMed ID: 16206215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical and clinical aspects on the use of amifostine as chemoprotector in neuroblastoma patients.
    Fulda S; Fichtner I; Hero B; Berthold F
    Med Pediatr Oncol; 2001 Jan; 36(1):199-202. PubMed ID: 11464883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose chemotherapy with autologous stem cell rescue in children with nephroblastoma.
    Kremens B; Gruhn B; Klingebiel T; Hasan C; Laws HJ; Koscielniak E; Hero B; Selle B; Niemeyer C; Finckenstein FG; Schulz A; Wawer A; Zintl F; Graf N
    Bone Marrow Transplant; 2002 Dec; 30(12):893-8. PubMed ID: 12476282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Differentiated treatment protocols for high- and standard-risk hepatoblastoma--an interim report of the German Liver Tumor Study HB99].
    Häberle B; Bode U; von Schweinitz D
    Klin Padiatr; 2003; 215(3):159-65. PubMed ID: 12778356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fractionated total body irradiation, high-dose melphalan, etoposide, and carboplatin (FTBI-MEC) for autologous stem cell transplantation in children with advanced neuroblastoma and primitive neuroectodermal tumor.
    Emminger W; Gadner H
    Pediatr Hematol Oncol; 1992; 9(2):183-5. PubMed ID: 1356004
    [No Abstract]   [Full Text] [Related]  

  • 20. Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation.
    Spencer A; Horvath N; Gibson J; Prince HM; Herrmann R; Bashford J; Joske D; Grigg A; McKendrick J; Prosser I; Lowenthal R; Deveridge S; Taylor K;
    Bone Marrow Transplant; 2005 May; 35(10):971-7. PubMed ID: 15778725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.